Novartis will present new data from 31 abstracts across its industry-leading immunology portfolio at the European Alliance of Associations for Rheumatology (EULAR) Congress on June 3-6 in London, advancing scientific insight into high-burden autoimmune diseases.
“Novartis is committed to shaping the future of immunology. From small molecules to biologics and CAR-T cell therapy, our pioneering science is focused on where we can have the greatest impact on patient outcomes,” said Angelika Jahreis, global head, immunology development, Novartis. “At EULAR, we will share compelling new data for Cosentyx, ianalumab and our CAR-T therapy rap-cel across diseases where there is high unmet need. These data demonstrate how Novartis innovation can have meaningful impact for people living with autoimmune diseases like polymyalgia rheumatica, Sjogren’s disease, systemic lupus erythematosus and systemic sclerosis.”
Novartis advancing bold science with the goal of bringing relief and a renewed sense of hope to people living with autoimmune diseases. Building on its legacy of first-in-class innovation across rheumatology, dermatology and allergy, and a diverse industry-leading pipeline, the company committed to shaping what’s next in immunology.
Novartis is an innovative medicines company. Every day, it work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Its medicines reach more than 300 million people worldwide. |